首页 > 最新文献

Allergo Journal International最新文献

英文 中文
Coronavirus infection in an unvaccinated atopic dermatitis patient under ongoing dupilumab therapy: eczema flare-up, but moderate COVID-19 symptoms 正在接受dupilumab治疗的未接种疫苗的特应性皮炎患者的冠状病毒感染:湿疹脱落,但有中度新冠肺炎症状
Q3 Medicine Pub Date : 2023-02-01 DOI: 10.1007/s40629-023-00245-w
Natalie Anasiewicz MD, Corsin Seeli MD, Marie-Charlotte Brüggen MD, PhD,  Matthias Möhrenschlager MD
{"title":"Coronavirus infection in an unvaccinated atopic dermatitis patient under ongoing dupilumab therapy: eczema flare-up, but moderate COVID-19 symptoms","authors":"Natalie Anasiewicz MD, Corsin Seeli MD, Marie-Charlotte Brüggen MD, PhD,  Matthias Möhrenschlager MD","doi":"10.1007/s40629-023-00245-w","DOIUrl":"10.1007/s40629-023-00245-w","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-023-00245-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9237392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allergen immunotherapy in house dust mite-associated allergic rhinitis: efficacy of the 300 IR mite tablet 过敏原免疫疗法治疗屋尘螨相关性过敏性鼻炎:300红外螨片的疗效
Q3 Medicine Pub Date : 2023-01-31 DOI: 10.1007/s40629-022-00241-6
Ludger Klimek, Randolf Brehler, Ingrid Casper, Felix Klimek, Jan Hagemann, Mandy Cuevas,  Karl-Christian Bergmann

Background

A perennial house dust mite-associated allergic rhinitis has a major impact on the quality of life of patients and is associated with a high socioeconomic burden. The most common symptoms of allergic rhinitis include a runny nose and nasal congestion, sneezing, itching of nose, mouth and/or throat, and/or ocular symptoms. Affected patients often develop allergic bronchial asthma. Therapy options for allergic rhinitis include allergen avoidance, symptomatic treatment, and allergen immunotherapy. Allergen immunotherapy is the only disease-modifying treatment that can permanently alleviate the symptoms of allergic rhinitis. In July 2021, a new sublingual mite tablet was approved in Germany.

Methods

This review summarizes clinical studies on the 300 IR (index of reactivity) mite tablet in adolescents and adults with house dust mite-associated allergic rhinitis and presents the results.

Results

In the phase II and phase III studies considered here, different dosages of the mite tablet were investigated. The 300 IR mite tablet showed the best benefit–risk profile and has been approved in Europe, Japan, South Korea, Australia, and New Zealand for the treatment of house dust mite-associated allergic rhinitis.

Conclusion

Allergen immunotherapy with the 300 IR mite tablet is an effective treatment that relieves allergic symptoms, reduces the need for symptomatic medication, and improves the quality of life in both adults and adolescents with house dust mite-associated allergic rhinitis. At the same time, treatment with the 300 IR mite tablet is well tolerated. Mild to moderate reactions at the application site subside after a few days.

背景常年性屋尘螨相关性过敏性鼻炎对患者的生活质量有重大影响,并与较高的社会经济负担有关。过敏性鼻炎最常见的症状包括流鼻涕和鼻塞、打喷嚏、鼻子、嘴巴和/或喉咙发痒和/或眼部症状。受影响的患者经常发展为过敏性支气管哮喘。过敏性鼻炎的治疗选择包括避免过敏原、症状治疗和过敏原免疫治疗。过敏原免疫疗法是唯一可以永久缓解过敏性鼻炎症状的疾病改良疗法。2021年7月,一种新的舌下螨片在德国获得批准。方法本综述总结了300 IR(反应指数)螨片在患有屋尘螨相关过敏性鼻炎的青少年和成人中的临床研究,并介绍了结果。结果在本文考虑的II期和III期研究中,研究了不同剂量的螨片。300 IR螨片显示出最佳的获益-风险状况,已在欧洲、日本、韩国、澳大利亚和新西兰被批准用于治疗屋尘螨相关的过敏性鼻炎。结论用300 IR螨片进行过敏原免疫治疗是一种有效的治疗方法,可以缓解成人和青少年屋尘螨相关性过敏性鼻炎的过敏症状,减少症状药物的需要,提高生活质量。同时,用300IR螨片治疗是耐受性良好的。施用部位的轻度至中度反应在几天后消退。
{"title":"Allergen immunotherapy in house dust mite-associated allergic rhinitis: efficacy of the 300 IR mite tablet","authors":"Ludger Klimek,&nbsp;Randolf Brehler,&nbsp;Ingrid Casper,&nbsp;Felix Klimek,&nbsp;Jan Hagemann,&nbsp;Mandy Cuevas,&nbsp; Karl-Christian Bergmann","doi":"10.1007/s40629-022-00241-6","DOIUrl":"10.1007/s40629-022-00241-6","url":null,"abstract":"<div><h3>Background</h3><p>A perennial house dust mite-associated allergic rhinitis has a major impact on the quality of life of patients and is associated with a high socioeconomic burden. The most common symptoms of allergic rhinitis include a runny nose and nasal congestion, sneezing, itching of nose, mouth and/or throat, and/or ocular symptoms. Affected patients often develop allergic bronchial asthma. Therapy options for allergic rhinitis include allergen avoidance, symptomatic treatment, and allergen immunotherapy. Allergen immunotherapy is the only disease-modifying treatment that can permanently alleviate the symptoms of allergic rhinitis. In July 2021, a new sublingual mite tablet was approved in Germany.</p><h3>Methods</h3><p>This review summarizes clinical studies on the 300 IR (index of reactivity) mite tablet in adolescents and adults with house dust mite-associated allergic rhinitis and presents the results.</p><h3>Results</h3><p>In the phase II and phase III studies considered here, different dosages of the mite tablet were investigated. The 300 IR mite tablet showed the best benefit–risk profile and has been approved in Europe, Japan, South Korea, Australia, and New Zealand for the treatment of house dust mite-associated allergic rhinitis.</p><h3>Conclusion</h3><p> Allergen immunotherapy with the 300 IR mite tablet is an effective treatment that relieves allergic symptoms, reduces the need for symptomatic medication, and improves the quality of life in both adults and adolescents with house dust mite-associated allergic rhinitis. At the same time, treatment with the 300 IR mite tablet is well tolerated. Mild to moderate reactions at the application site subside after a few days.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00241-6.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43680325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
High pan-allergen content in mango and peach in Taiwan 台湾芒果、桃子泛过敏原含量高
Q3 Medicine Pub Date : 2023-01-23 DOI: 10.1007/s40629-022-00240-7
Mey Fann Lee PhD, Yi Hsing Chen MD, PhD, Yu-Wen Chu PhD, Ping Cheng Hsieh MS, Nancy M. Wang PhD

Background

Many plant food allergens have been implicated in cross-reactivities and may cause repetitive pan-allergenic exposures, which increase the severity of patients’ allergic symptoms. Identification of allergenic protein levels in food allows for more precise dietary advice. This study aimed to determine LTP, profilin, and PR-10 in the 15 most popular fruits in Taiwan.

Methods

cDNA encoding profilin (Sola l 1), nonspecific lipid transfer protein (nsLTP, Sola l 3), and pathogenesis-related protein (PR-10, Sola l 4) were cloned into the pQE30, expressed in Escherichia coli, and purified. Extracts of the most popular fruits, including apple, banana, carrot, celery, dragon fruit, hami melon, jujube, kiwi, mango, melon, orange, papaya, peach, persimmon, and tomato, in Taiwan were prepared in PBS. The allergenic protein levels in these extracts were determined by immuno-dot blotting using rabbit anti-rSola l 1, 3, and 4 polyclonal antibodies.

Results

Among all 15 fruit extracts tested, peach and mango contained the highest levels of profilin, nsLTP, and PR-10. Papaya, melon, and tomato contained low but detectable levels of the three pan-allergens.

Conclusion

Our data suggest that peach and mango contain the highest levels of important pan-allergens among the 15 common fruits tested, which agrees with epidemiological data.

背景许多植物性食物过敏原与交叉反应有关,可能导致反复的泛致敏暴露,从而增加患者过敏症状的严重程度。识别食物中的致敏蛋白水平可以提供更精确的饮食建议。本研究旨在检测台湾15种最常见水果中的LTP、profilin和PR-10。方法将编码profilin(Sola l 1)、非特异性脂质转移蛋白(nsLTP,Sola l 3)和病原体相关蛋白(PR-10,Sola 1 4)的DNA克隆到pQE30中,在大肠杆菌中表达并纯化。在PBS中制备了台湾最受欢迎的水果提取物,包括苹果、香蕉、胡萝卜、芹菜、火龙果、哈密瓜、大枣、猕猴桃、芒果、甜瓜、桔子、木瓜、桃、柿子和番茄。使用兔抗rSola l 1、3和4多克隆抗体通过免疫斑点印迹法测定这些提取物中的致敏蛋白水平。结果在所检测的15种水果提取物中,桃和芒果的profilin、nsLTP和PR-10含量最高。木瓜、甜瓜和番茄含有较低但可检测到的三种泛过敏原。结论我们的数据表明,在测试的15种常见水果中,桃和芒果含有最高水平的重要泛过敏原,这与流行病学数据一致。
{"title":"High pan-allergen content in mango and peach in Taiwan","authors":"Mey Fann Lee PhD,&nbsp;Yi Hsing Chen MD, PhD,&nbsp;Yu-Wen Chu PhD,&nbsp;Ping Cheng Hsieh MS,&nbsp;Nancy M. Wang PhD","doi":"10.1007/s40629-022-00240-7","DOIUrl":"10.1007/s40629-022-00240-7","url":null,"abstract":"<div><h3>Background</h3><p>Many plant food allergens have been implicated in cross-reactivities and may cause repetitive pan-allergenic exposures, which increase the severity of patients’ allergic symptoms. Identification of allergenic protein levels in food allows for more precise dietary advice. This study aimed to determine LTP, profilin, and PR-10 in the 15 most popular fruits in Taiwan.</p><h3>Methods</h3><p>cDNA encoding profilin (Sola l 1), nonspecific lipid transfer protein (nsLTP, Sola l 3), and pathogenesis-related protein (PR-10, Sola l 4) were cloned into the pQE30, expressed in <i>Escherichia coli</i>, and purified. Extracts of the most popular fruits, including apple, banana, carrot, celery, dragon fruit, hami melon, jujube, kiwi, mango, melon, orange, papaya, peach, persimmon, and tomato, in Taiwan were prepared in PBS. The allergenic protein levels in these extracts were determined by immuno-dot blotting using rabbit anti-rSola l 1, 3, and 4 polyclonal antibodies.</p><h3>Results</h3><p>Among all 15 fruit extracts tested, peach and mango contained the highest levels of profilin, nsLTP, and PR-10. Papaya, melon, and tomato contained low but detectable levels of the three pan-allergens.</p><h3>Conclusion</h3><p>Our data suggest that peach and mango contain the highest levels of important pan-allergens among the 15 common fruits tested, which agrees with epidemiological data.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00240-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42080272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Avoidance measures for mite allergy—an update 螨类过敏的预防措施——最新进展
Q3 Medicine Pub Date : 2023-01-23 DOI: 10.1007/s40629-022-00242-5
Ludger Klimek, Randolf Brehler, Karl-Christian Bergmann, Ingrid Casper, Felix Klimek, Jan Hagemann, Marie-Luise Polk,  Mandy Cuevas M.D.

House dust mites are a major source of allergens in house dust and, thus, the main trigger of perennial allergic respiratory diseases [1,2,3,4,5]. Scientific research on the life cycle, diet, and reproductive behavior of dust mites and on the biology of mite allergens has uncovered mechanisms leading to the development of respiratory allergies and suggests measures that can minimize exposure to dust mite allergens. Here, we discuss the evidence linking house dust mite exposure and respiratory allergies and present the efficacy of avoidance measures and their scientific evidence.

房屋尘螨是房屋灰尘中过敏原的主要来源,因此也是常年过敏性呼吸道疾病的主要诱因[1,2,3,4,5]。对尘螨的生命周期、饮食和生殖行为以及尘螨过敏原生物学的科学研究揭示了导致呼吸道过敏的机制,并提出了可以尽量减少接触尘螨过敏源的措施。在这里,我们讨论了将屋尘螨暴露与呼吸道过敏联系起来的证据,并介绍了避免措施的有效性及其科学证据。
{"title":"Avoidance measures for mite allergy—an update","authors":"Ludger Klimek,&nbsp;Randolf Brehler,&nbsp;Karl-Christian Bergmann,&nbsp;Ingrid Casper,&nbsp;Felix Klimek,&nbsp;Jan Hagemann,&nbsp;Marie-Luise Polk,&nbsp; Mandy Cuevas M.D.","doi":"10.1007/s40629-022-00242-5","DOIUrl":"10.1007/s40629-022-00242-5","url":null,"abstract":"<div><p>House dust mites are a major source of allergens in house dust and, thus, the main trigger of perennial allergic respiratory diseases [1,2,3,4,5]. Scientific research on the life cycle, diet, and reproductive behavior of dust mites and on the biology of mite allergens has uncovered mechanisms leading to the development of respiratory allergies and suggests measures that can minimize exposure to dust mite allergens. Here, we discuss the evidence linking house dust mite exposure and respiratory allergies and present the efficacy of avoidance measures and their scientific evidence.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00242-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42036595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validity of anamnestic data on allergies towards β-lactam antibiotics in a preoperative setting 术前对β-内酰胺类抗生素过敏的记忆数据的有效性
Q3 Medicine Pub Date : 2023-01-10 DOI: 10.1007/s40629-022-00238-1
Katharina Luwich, Eva Lücke, Thomas Hachenberg, Sabine Stegemann-Koniszewski, Robin John, Rüdiger Braun-Dullaeus, Jens Schreiber
{"title":"Validity of anamnestic data on allergies towards β-lactam antibiotics in a preoperative setting","authors":"Katharina Luwich,&nbsp;Eva Lücke,&nbsp;Thomas Hachenberg,&nbsp;Sabine Stegemann-Koniszewski,&nbsp;Robin John,&nbsp;Rüdiger Braun-Dullaeus,&nbsp;Jens Schreiber","doi":"10.1007/s40629-022-00238-1","DOIUrl":"10.1007/s40629-022-00238-1","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00238-1.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44485484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety in switching Hymenoptera venom immunotherapy manufacturers 膜翅目毒液免疫治疗厂家切换的安全性
Q3 Medicine Pub Date : 2022-12-30 DOI: 10.1007/s40629-022-00237-2
Mariana Bragança MD, Daniela Brandão Abreu MD, Luís Amaral MD, José Luís Plácido MD, Alice Coimbra MD
{"title":"Safety in switching Hymenoptera venom immunotherapy manufacturers","authors":"Mariana Bragança MD,&nbsp;Daniela Brandão Abreu MD,&nbsp;Luís Amaral MD,&nbsp;José Luís Plácido MD,&nbsp;Alice Coimbra MD","doi":"10.1007/s40629-022-00237-2","DOIUrl":"10.1007/s40629-022-00237-2","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00237-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48194017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of medications for antihistamine-refractory chronic spontaneous urticaria: a systematic review and network meta-analysis 抗组胺药治疗难治性慢性自发性荨麻疹的疗效和安全性:系统综述和网络荟萃分析
Q3 Medicine Pub Date : 2022-12-21 DOI: 10.1007/s40629-022-00235-4
Benjamin Kendziora M.D. Ph.D., Jessica Frey,  Markus Reinholz M.D. Ph.D.,  Franziska Ruëff M.D., Eva Oppel M.D.,  Torsten Zuberbier M.D.,  Daniela Hartmann M.D. Ph.D., Justin G. Schlager M.D.,  Lars E. French M.D.

Summary

Purpose

Most medications for antihistamine-refractory chronic spontaneous urticaria (CSU) have not been compared head-to-head. This systematic review and network meta-analysis evaluates their relative efficacy and safety.

Methods

Electronic databases were searched until 05 May 2022 for randomized controlled trials investigating systemic medications for antihistamine-refractory CSU. The change in the urticaria activity score over seven days (UAS7) and occurrence of adverse events were compared between treatments using random-effects network meta-analysis models.

Results

In all, 32 studies with 3641 patients receiving 31 different systemic medical interventions were included. Among currently available drugs, omalizumab 300 mg injected every 4 weeks and cyclosporine 3–5 mg/kg daily per os were most effective in reducing the UAS7 with a reduction of −10.45 (95% confidence interval [CI]: −12.35, −8.55) and of −10.40 (95% CI: −19.4, −1.4) compared to placebo. Similar efficacies were shown by the nonapproved agents ligelizumab 72 mg injected every 4 weeks (−11.67, 95% CI: −16.80, −7.15) and fenebrutinib 400 mg daily per os (−9.50, 95% CI: −17.56, −1.44). The odds ratio for the occurrence of an adverse event with placebo as comparator was 1.09 for omalizumab (95% CI: 0.83, 1.42), 2.16 for cyclosporine (95% CI: 0.77, 6.07: GRADE; moderate certainty), 0.89 for ligelizumab (95% CI: 0.47, 1.69), and 2.14 for fenebrutinib (95% CI: 0.62, 7.38) in the mentioned dosages.

Conclusion

Omalizumab 300 mg injected every 4 weeks and cyclosporine 3–5 mg/kg daily per os are the most effective currently available drugs for antihistamine-refractory CSU. Cyclosporine shows a relatively less favorable safety profile.

摘要目的大多数治疗抗组胺药难治性慢性自发性荨麻疹(CSU)的药物尚未进行正面比较。这项系统综述和网络荟萃分析评估了它们的相对疗效和安全性。方法检索电子数据库,直到2022年5月5日,以进行随机对照试验,研究抗组胺难治性CSU的全身药物治疗。使用随机效应网络荟萃分析模型比较两种治疗之间7天内荨麻疹活动评分(UAS7)的变化和不良事件的发生。结果共纳入32项研究,3641名患者接受了31种不同的系统性医疗干预。在目前可用的药物中,奥马珠单抗300 每4周注射mg,环孢菌素3-5 与安慰剂相比,每天口服mg/kg最有效地降低了UAS7,降低了−10.45(95%置信区间[CI]:−12.35,−8.55)和−10.40(95%可信区间:−19.4,−1.4)。未经批准的药物利格列珠单抗72也显示出类似的疗效 mg每4周注射一次(−11.67,95%置信区间:−16.80,−7.15)和非尼布替尼400 mg每日口服(−9.50,95%可信区间:−17.56,−1.44)。以安慰剂为对照,在上述剂量下,奥马珠单抗发生不良事件的比值比为1.09(95%可信区间为0.83,1.42),环孢菌素发生不良事件为2.16(95%可信范围为0.77,6.07:GRADE;中度确定性),利格列珠单抗发生不利事件的比值比为0.89(95%置信区间为0.47,1.69),非尼布替尼发生不良事件(95%可信系数为0.62,7.38)。结论奥马珠单抗300 每4周注射mg,环孢菌素3-5 每日口服mg/kg是目前治疗抗组胺难治性CSU最有效的药物。环孢菌素的安全性相对较差。
{"title":"Efficacy and safety of medications for antihistamine-refractory chronic spontaneous urticaria: a systematic review and network meta-analysis","authors":"Benjamin Kendziora M.D. Ph.D.,&nbsp;Jessica Frey,&nbsp; Markus Reinholz M.D. Ph.D.,&nbsp; Franziska Ruëff M.D.,&nbsp;Eva Oppel M.D.,&nbsp; Torsten Zuberbier M.D.,&nbsp; Daniela Hartmann M.D. Ph.D.,&nbsp;Justin G. Schlager M.D.,&nbsp; Lars E. French M.D.","doi":"10.1007/s40629-022-00235-4","DOIUrl":"10.1007/s40629-022-00235-4","url":null,"abstract":"<div><h2>Summary</h2><div><h3>Purpose</h3><p>Most medications for antihistamine-refractory chronic spontaneous urticaria (CSU) have not been compared head-to-head. This systematic review and network meta-analysis evaluates their relative efficacy and safety.</p><h3>Methods</h3><p>Electronic databases were searched until 05 May 2022 for randomized controlled trials investigating systemic medications for antihistamine-refractory CSU. The change in the urticaria activity score over seven days (UAS7) and occurrence of adverse events were compared between treatments using random-effects network meta-analysis models.</p><h3>Results</h3><p>In all, 32 studies with 3641 patients receiving 31 different systemic medical interventions were included. Among currently available drugs, omalizumab 300 mg injected every 4 weeks and cyclosporine 3–5 mg/kg daily per os were most effective in reducing the UAS7 with a reduction of −10.45 (95% confidence interval [CI]: −12.35, −8.55) and of −10.40 (95% CI: −19.4, −1.4) compared to placebo. Similar efficacies were shown by the nonapproved agents ligelizumab 72 mg injected every 4 weeks (−11.67, 95% CI: −16.80, −7.15) and fenebrutinib 400 mg daily per os (−9.50, 95% CI: −17.56, −1.44). The odds ratio for the occurrence of an adverse event with placebo as comparator was 1.09 for omalizumab (95% CI: 0.83, 1.42), 2.16 for cyclosporine (95% CI: 0.77, 6.07: GRADE; moderate certainty), 0.89 for ligelizumab (95% CI: 0.47, 1.69), and 2.14 for fenebrutinib (95% CI: 0.62, 7.38) in the mentioned dosages.</p><h3>Conclusion</h3><p>Omalizumab 300 mg injected every 4 weeks and cyclosporine 3–5 mg/kg daily per os are the most effective currently available drugs for antihistamine-refractory CSU. Cyclosporine shows a relatively less favorable safety profile.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00235-4.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47243749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Papuloerythroderma of Ofuji (PEO) successfully treated with acitretin 阿维素治疗富士丘疹红皮病(PEO)成功
Q3 Medicine Pub Date : 2022-12-01 DOI: 10.1007/s40629-022-00236-3
Gabriela Blanchard MD, PhD,  Emmanuella Guenova MD, PhD
{"title":"Papuloerythroderma of Ofuji (PEO) successfully treated with acitretin","authors":"Gabriela Blanchard MD, PhD,&nbsp; Emmanuella Guenova MD, PhD","doi":"10.1007/s40629-022-00236-3","DOIUrl":"10.1007/s40629-022-00236-3","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00236-3.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41355896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Localized eczematous rash affecting left and right regions of breast and shoulder after Ad26.COV2.S vaccine against COVID-19 in a 30-year-old woman with comorbidities 一名患有合并症的30岁女性接种新冠肺炎Ad26.COV2.S疫苗后,乳腺和肩部左右区域出现局部湿疹样皮疹
Q3 Medicine Pub Date : 2022-11-28 DOI: 10.1007/s40629-022-00234-5
Natalie Anasiewicz, Corsin Seeli, Marie-Charlotte Brüggen, Matthias Möhrenschlager
{"title":"Localized eczematous rash affecting left and right regions of breast and shoulder after Ad26.COV2.S vaccine against COVID-19 in a 30-year-old woman with comorbidities","authors":"Natalie Anasiewicz,&nbsp;Corsin Seeli,&nbsp;Marie-Charlotte Brüggen,&nbsp;Matthias Möhrenschlager","doi":"10.1007/s40629-022-00234-5","DOIUrl":"10.1007/s40629-022-00234-5","url":null,"abstract":"","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00234-5.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9482020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinic and diagnostics of house dust mite allergy 屋尘螨过敏的临床与诊断
Q3 Medicine Pub Date : 2022-11-24 DOI: 10.1007/s40629-022-00232-7
Randolf Brehler

Summary

House dust mite allergens are common triggers for allergic rhinoconjunctivitis and allergic asthma; they can aggravate atopic dermatitis and rarely lead to anaphylactic reactions due to dust mite allergens in food. Typical symptoms are nasal obstruction, sneezing, and irritation, and more often than in pollen allergy, allergic asthma also develops. The symptomatology exists in principle throughout the year with maximum complaints in autumn and winter. Of particular importance are sleep disturbances due to nasal obstruction, which lead to restrictions in the quality of life and performance of affected patients. Sensitization can be proven by skin tests and detection of serum allergen-specific IgE antibodies; proof of allergy is achieved by nasal or conjunctival provocation tests. The diagnosis of local allergic rhinitis can only be made by provocation or by determination of allergen-specific IgE antibodies in nasal secretions. The quality of the allergen extract used is essential for all tests; it must contain the allergens to which a patient is sensitized. The concentration of Der p 23 in house dust mite extracts is particularly critical.

SummaryHouse尘螨过敏原是过敏性鼻结膜炎和过敏性哮喘的常见诱因;它们会加重特应性皮炎,很少因食物中的尘螨过敏原而引起过敏反应。典型的症状是鼻塞、打喷嚏和刺激,而且比花粉过敏更常见的是,还会出现过敏性哮喘。症状学原则上全年都存在,秋季和冬季症状最多。特别重要的是鼻阻塞引起的睡眠障碍,这会限制受影响患者的生活质量和表现。可以通过皮肤测试和血清过敏原特异性IgE抗体的检测来证明致敏作用;通过鼻腔或结膜刺激试验来证明过敏。局部过敏性鼻炎的诊断只能通过激发或通过测定鼻腔分泌物中的过敏原特异性IgE抗体来进行。所用过敏原提取物的质量对所有测试至关重要;它必须含有患者对其敏感的过敏原。Der p 23在屋尘螨提取物中的浓度是特别关键的。
{"title":"Clinic and diagnostics of house dust mite allergy","authors":"Randolf Brehler","doi":"10.1007/s40629-022-00232-7","DOIUrl":"10.1007/s40629-022-00232-7","url":null,"abstract":"<div><h2>Summary</h2><div><p>House dust mite allergens are common triggers for allergic rhinoconjunctivitis and allergic asthma; they can aggravate atopic dermatitis and rarely lead to anaphylactic reactions due to dust mite allergens in food. Typical symptoms are nasal obstruction, sneezing, and irritation, and more often than in pollen allergy, allergic asthma also develops. The symptomatology exists in principle throughout the year with maximum complaints in autumn and winter. Of particular importance are sleep disturbances due to nasal obstruction, which lead to restrictions in the quality of life and performance of affected patients. Sensitization can be proven by skin tests and detection of serum allergen-specific IgE antibodies; proof of allergy is achieved by nasal or conjunctival provocation tests. The diagnosis of local allergic rhinitis can only be made by provocation or by determination of allergen-specific IgE antibodies in nasal secretions. The quality of the allergen extract used is essential for all tests; it must contain the allergens to which a patient is sensitized. The concentration of Der p 23 in house dust mite extracts is particularly critical.</p></div></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-022-00232-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48036561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Allergo Journal International
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1